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Norman Barrett, a surgeon from St. Thomas' Hospital,
first described Barrett's oesophagus in 1950 [1]. He
described two variants of columnar-lined (Barrett's)
oesophagus (CLO): a congenitally short oesophagus with
intra-thoracic gastric epithelium and congenital gastric
heterotopia in the oesophagus, with ulceration. Three
years later, Allison, a surgeon from Oxford, provided
sound anatomical reasons why a columnar lining could
occur in the oesophagus as an acquired condition that
appeared to be prevalent in patients with gastro-oesopha-
geal reflux [2]. Subsequently, several authors confirmed
the association of CLO with clinical gastro-oesophageal
reflux [3,4] and subsequent studies confirmed the devel-
opment of CLO following induction of gastro-oesopha-
geal reflux in an animal model [5].
It became apparent from the histological standpoint that
the columnar lined oesophagus embraced a spectrum of
different cellular types, principally comprising a gastric
fundic type epithelium, a junctional type epithelium,
which had similarities to gastric mucosa but did not
secrete digestive juices, although possessing the ability to
withstand acid-peptic digestion, and a distinctive type of
intestinal metaplasia, characterised by the presence of
goblet cells [6]. The malignant potential of the columnar
lined oesophagus was subsequently described [7,8],
which conferred great importance on the condition and
consequently on its accurate diagnosis. For this reason,
and in order to eliminate any confusion between CLO and
the normal junctional columnar epithelium, as well as
difficulty in identifying the precise oesophago-gastric
junction in cases of hiatal hernia, an arbitrary minimal
length of 3 cm of CLO from the oesophago-gastric junc-
tion was recommended before the diagnosis of CLO
should be made [9]. Until the last few years, Barrett's
oesophagus was defined as any histological type of
columnar epithelium with a minimum length of 3 cm
above the oesophago-gastric junction.
If viewed from the standpoint of the risk of developing
adenocarcinoma, it became apparent that this applied
only to CLO with intestinal metaplasia (IM) and that CLO
with fundic epithelium had no malignant potential
[10,11]. However, endoscopic appearances did not distin-
guish between the various histological types and all com-
prised "Barrett's oesophagus" and were all included in the
initial surveillance programmes, which resulted in a much
lower incidence of adenocarcinoma than more recent
series which have documented the risk in patients with
intestinal metaplasia. The problem of definition has
become more clouded with the realisation that short seg-
ments of columnar lined oesophagus with intestinal
metaplasia, less than 3 cm in length, can be associated
with the development of adenocarcinoma and even in
short, non-circumferential tongues of columnarisation
[12]. These two entities have each been referred to as
"short segment Barrett's" since the length of these seg-
ments, which have malignant potential, fall short of the 3
cm required to fulfil the traditional definition. Subse-
quent studies have shown that such short and usually
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with intestinal metaplasia are visible in 42% of adenocar-
cinoma of the cardia when detailed pathological examina-
tion is undertaken [13,14]. Furthermore,
pathophysiological studies have shown that patients with
these short segments of columnarisation have gastro-
oesophageal reflux disease, the pathophysiological sever-
ity of which is intermediate between that in patients with
erosive oesophagitis and those with "traditional Barrett's
CLO" [15].
The problem of definition has been further compounded
by numerous reports of microscopic intestinal metaplasia
around the oesophago-gastric junction, present in up to
36% of patients undergoing endoscopy for a variety of
gastro-intestinal symptoms, and some have referred to
this phenomenon also as "short-segment Barrett's or
"ultra-short segment Barrett's" [16-18]. In Spechler's series
[16], only patients with "traditional Barrett's oesophagus"
and those with microscopic intestinal metaplasia at the
cardia were studied, those patients with confluent or cir-
cumferential columnarisation seen endoscopically were
excluded from the study. The bulk of evidence suggests
that microscopic intestinal metaplasia at the cardia is not
associated with gastro-oesophageal reflux disease, but
associated principally with increasing age and Helico-
bacter infection. It is believed to have a different histogen-
esis from intestinal metaplasia in confluent and
circumferential areas of columnarisation in the oesopha-
gus, and its risk of malignant change appears to be
extremely low [19]. In these circumstances, there is confu-
sion in using the term "short segment Barrett's" inter-
changeably between endoscopically visible confluent or
circumferential columnarisation with intestinal metapla-
sia and microscopic intestinal metaplasia around the car-
dia, and furthermore it would appear entirely
inappropriate to apply the term "Barrett's oesophagus" at
all to the latter group, in the absence of endoscopically
visible columnarisation, gastro-oesophageal reflux dis-
ease and a significant malignant risk.
Pathophysiology
It is now well established that CLO is a complication of
severe and long-standing gastro-oesophageal reflux and is
found in 10–16% of such patients at endoscopy [20].
Pathophysiological studies have shown that patients with
Barrett's CLO show a higher proportion of lower oesopha-
geal sphincter failure, and peristaltic dysfunction than
patients with erosive oesophagitis and over 90% have an
associated hiatal hernia [21]. CLO is also associated with
higher levels of acid exposure than erosive oesophagitis
and duodeno-gastro-oesophageal exposure as measured
by Bilitec monitoring, particularly in the presence of com-
plications [22,23]. Therefore, patients with CLO are at the
extreme end of the pathophysiological spectrum of gastro-
oesophageal reflux disease. This is compounded by the
fact that symptoms may be minimal or absent due to
impaired sensitivity of the columnar lining to acid per-
fusion [24]. As a consequence of this, many cases of CLO
remain undiagnosed. In a clinical and autopsy study per-
formed in the USA, the incidence at endoscopy was 18 per
100,000 population, whereas at autopsy the correspond-
ing figure was 376 per 100,000, with only 5% becoming
clinically apparent [25]. However, this figure was subse-
quently revised to 20% with increasing use of endoscopy
[26].
Epidemiology
Barrett's (columnar-lined) oesophagus (CLO) is an
important condition because, together with gastroesopha-
geal reflux disease (GORD), it is the only known precursor
of oesophageal adenocarcinoma (AC) [27,28]. Like AC,
the prevalence of CLO has also been rising in Europe and
North America, whereas in the USA the increase in CLO
parallels the increase in the number of upper gastrointes-
tinal endoscopies [29], in the UK there has been a real
increase in the numbers diagnosed which exceeds the
increased performance of upper gastrointestinal endos-
copy [30-32]. Although the majority of CLO will not
progress to malignancy it is important to identify relevant
risk factors associated with such progression.
In an analysis of 5317 CLO cases in the UK it was found
that fewer than 5% developed AC [33]. Most of these
(approximately 80%) were prevalent cancers, i.e. cancer
arising within one year of CLO diagnosis and about 20%
were incident cancers, i.e. those arising more than one
year after CLO diagnosis. It is not known whether AC can
develop without passing through the CLO stage. A recent
study [28] has shown only a modest increase in the
oesophageal cancer risk in GORD patients having no
record of CLO. The rate at which CLO progresses through
increasingly severe dysplasia to AC is between 1 in 44 and
1 in 441 patient years [34,27]. This is 30 – 125 times the
rate of AC development in the general population [35].
H-pylori infection
The role of H-pylori infection in the development of CLO
and its progression to AC is still very controversial and
thus will not be discussed in any detail here. Vieth et al,
(2000) [36] have shown that patients who have GORD
and are infected with H-pylori have no increased risk of
developing either CLO or AC and they concluded that
since H-pylori infection is significantly less frequent in
patients with GORD than in patients with non-ulcer dys-
pepsia it is possible that H-pylori infection may have a pro-
tective effect. There is certainly an increase in CLO in the
USA and Europe concomitant with a decline in the preva-
lence of infection with H-pylori in these populations, and
this and the effect of therapy with proton pump inhibitorsPage 2 of 21
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(2002) [38].
Characteristics of Barrett's oesophagus patients
There are a number of studies showing the basic character-
istics of CLO patients and some of these are summarised
in Table 1.
Most European studies, from the UK and The Nether-
lands, show a male predominance of CLO, whereas the
studies from Australia and Chile do not, and all but three
of these studies have fewer than 300 CLO patients. The
mean age at diagnosis is over 60 years in Europe, but 50.8
years and 53.0 years respectively in Australia and Chile. It
is not possible at this stage to speculate as to the reason for
this. In all but one study the mean age at diagnosis was
greater for females than males by almost a decade. In an
analysis of CLO from a single UK centre over 15 years it
was found that prevalence rose incrementally from age
20–29 years, from 0.16% in males and 0% in females, to
a maximum at age 70–79 years, of 4.89% in males and
3.75% in females. Although there was a steep rise in prev-
alence with age in both sexes, it was slower in females
between the ages of 20–59 than in males, and this was
reflected in a 10-year delay in the onset of CLO in females.
One could speculate that premenopausal females are pro-
tected to some degree against the development of CLO by
their hormones [47].
Life style factors affecting CLO development
There are very few studies on lifestyle factors and CLO
thus making it impossible to say anything concrete at this
stage. The available evidence suggests that neither alcohol
consumption nor tobacco use have an effect (Table 2).
One study [50] found the past smoking to be moderately
connected with CLO development, possibly as a result of
the effect of smoking on promoting gastroesophageal
reflux. Another study [48] suggested a role for obesity in
young CLO patients. In this context it is of interest that
CLO occurs as a complication of long standing GORD
[20] which, itself, is a complication of obesity.
The UK National Barrett's Oesophagus Registry
Because of growing concern about the rise in the inci-
dence of both AC and CLO The UK National Barrett's
Oesophagus Registry (UKBOR) was established in June
1996. The aims of the Registry were to establish a national
database of all cases of CLO in the UK in order to learn
more about the aetiology, epidemiology and natural his-
tory of CLO and to provide a co-ordinating infrastructure
for prospective studies. The primary aim being the identi-
fication of those sub-groups of CLO most at risk of devel-
oping AC so that targeted surveillance strategies can be
implemented. This is the world's first such registry, and
was set up as a joint initiative of the Oesophageal Section
of the British Society of Gastroenterology and the Euro-
pean Cancer Prevention Organization (ECP) [51]. Since
then almost 9500 CLO patients have been registered from
42 hospitals nationwide. In the following section we give
an overview of the data, for the UK, from studying UKBOR
patients.
Results of studies from UKBOR
The results of studies using the expanding UKBOR data-
base are summarised in table 3.
A single centre's 20 years' experience of columnar-lined (Barrett's) 
oesophagus diagnosis
All upper GI endoscopy and histology reports from Wex-
ham Park Hospital, Slough, Southern England between
Jan 1977 and Dec 1996 were reviewed and data from
patients with histologically proven CLO analysed in 5-
year bands [30]. The results are summarised in Table 3. It
is to be noted that there was an increasing number of
endoscopies and CLO diagnoses over time, CLO being
diagnosed more frequently in the last quinquenium com-
pared with the first.
Table 1: Characteristics of CLO patients
Ref Year Country N M:F Mean Age (Diagnosis) Type of study
M (Total) F
39 1992 UK 102 0.9 60.3 57.7 Consecutive surveillance patients
40 1996 Netherlands 166 1.4 62.0 Cohort
41 1997 UK 232 2.0 63.0 73.0 Prospective screening
18 1997 Australia 158 0.5 50.8 Consecutive SSB patients
42 1998 UK 268 1.7 60.2 70.0 Cohort
43 2000 UK 5717 1,7 61.4 67.5 Cohort
44 2000 UK 409 1.1 63.0 Cohort
45 2002 Chile 408 0.9 53.0 Consecutive endoscopy patients
46 2003 UK 232 1.7 - Consecutive endoscopy patientsPage 3 of 21
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Demographic data of 5,717 CLO patients from 27 UK
centres (each registering >50 patients with UKBOR) were
analysed [43]. All 27 hospitals provided data on sex and
date of birth; of these 23 also supplied date of diagnosis
of CLO and therefore, age at diagnosis could be calcu-
lated. Only 13 of the 27 hospitals were able to supply cur-
rent data on numbers of AC. The 27 centres were spread
geographically throughout the UK with 3 in Scotland, 3 in
Wales, 6 in Northern England, 4 in the Midlands and 11
in Southern England.
Table 4 shows the characteristics of CLO patients by geo-
graphical area in UK. There was little variation in M: F
ratio (1.3 – 1.7) and in mean age at diagnosis between the
centres, except for in males in Scotland where there was a
trend towards a lower age at diagnosis. Peak age at diag-
nosis of CLO in the 23 centres for males varied from 40–
49 to 70–79 years and in females varied from 60–69 to
70–79 years.
It is also worthy of note that these basic characteristics
changed little whether the analysis was done using 9 cen-
tres (2130 CLO patients) [52], 20 centres (4261 CLO
patients) [53] or 27 centres (5717 CLO Patients) [43], in
spite of the greatly increased numbers and greater geo-
graphical coverage.
Adenocarcinoma in CLO
Data for AC were available in 3880 (67.9%) CLO patients
from 13 centres. AC was confirmed in 136 (3.5%) (102
males and 34 females). The patient characteristics are
shown in Table 5. The M: F ratio of those with AC was 3.0,
almost twice that of CLO (1.7), suggesting that differences
in the rate of progression from CLO to AC are different in
the two sexes. Alternatively as males develop CLO at a
younger age their risk of progression to AC may be greater
as they have a longer time for the carcinogenic changes to
occur. We hope that studies currently in progress at
UKBOR will help to clarify this point.
Lifestyle Factors and CLO
This analysis was based at two centres in the UK and on
two separate studies. The reason for this was that at one
centre (Dundee, Scotland), both heights and weights were
available for nearly all patients enabling us to calculate
the BMI and thus it was decided to study lifestyle factors
with an observational study [48]. At the other centre
(Slough, southern England) height was almost never
recorded so it was decided that a case-control study was
the most appropriate study to give us information on life-
style factors.
Observational study – Dundee (Scotland)
The medical records of 136 CLO patients diagnosed
between March 1985 and October 1998 were examined.
Data recorded included height, weight, tobacco consump-
tion and alcohol intake. Body Mass Index (BMI) was cal-
culated (kg/m2) using the body weight nearest to and
preceding CLO diagnosis (Table 6). For analysis, tobacco
consumption and alcohol intake were graded to give a
score using the scoring system in the paper by Caygill et al
Table 2: Lifestyle risk factors for CLO
Ref Year Country Tobacco Alcohol Obesity
[48] 2002 UK - - +
[49] 1993 UK - - n/a
[50] 1990 UK + - n/a
Table 3: Detection rate of Barrett's oesophagus over a 20-year period at a single UK hospital.
Period Total no of endoscopies No of new CLO cases New CLO as a % of total endoscopies
Total Male Female
1/1/77–31/12/81 6500 12 6 6 0.2
1/1/82–31/12/86 10909 100 65 35 0.9
1/1/87–31/12/91 10812 129 84 45 1.2
1/1/92–31/12/96 16500 257 168 99 1.6
1/1/77–31/12/96 
(total)
44721 508 323 185 1.1Page 4 of 21
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shown that in Dundee there was a higher proportion
(43%) of young (<50 years) male CLO patients compared
to the other eight centres. The reasons for this are unclear
and remain to be established. Therefore in the above
study lifestyle factors were compared between those
below and above 50 years of age. The percentages of men
and women with either a tobacco score of 3 or more (i.e.
smokers, either current or within the last 10 years) or an
alcohol score of 3 or more (i.e. those drinking more than
that recommended by the government guidelines of 21
units for men and 14 units for women) were calculated
and subdivided into the two age groups. The results
showed that there did not appear to be a difference in
smoking or drinking habits between the older and
younger age groups, and these aspects of lifestyle do not
appear to be the cause of the high proportion of young
male CLO patients in Dundee.
It is generally accepted that individuals with a BMI of 30
or more are considered to be obese. In the general UK
population 11% of men and 13 % of women fulfil this cri-
terion [54] (The health of the nation: One year on). We,
therefore, calculated the BMI in the Dundee CLO patients
and divided them into the two age groups as for tobacco
and alcohol consumption. In this cohort of CLO patients
31% of men and 71% of women aged less than 50 years
were obese compared with 11% and 13% respectively in
the general population. In contrast, those aged more than
50 years had BMI, which were very similar to the general
population.
Table 4: CLO patient characteristics by geographical area in UK.
Geographical Area Total Males Females M:F
n mean age (yrs) mean age (yrs)
Scotland 563 57.4 65.3 1.4
Wales 388 61.4 66.4 1.9
England
North 1157 61.6 67.6 1.6
Midlands 1269 63.8 68.1 1.3
South 2340 61.6 67.7 1.7
Total 5717 62.0 67.5 1.7
Table 5: Adenocarcinoma in CLO
Total Males Females
No of AC 136 102 34
No of CLO 3880 2530 1350
Prevalence of AC in CLO (%) 3.5% 4.0% 2.5%
Mean age at diagnosis of AC (years) 67.0 64.7 74.0
Mean age at diagnosis of CLO (years) 63.5 61.4 67.5
Table 6: BMI for Barrett's oesophagus patients in dundee
Age
BMI > 30 (%) 0 – 49 50+ All
M 31 14 20
F 71 19 30
M+F 39 16 24Page 5 of 21
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Data on weight, alcohol and tobacco use were recorded in
case notes from this centre but not height, thus making it
impossible to calculate BMI. Accordingly a case-control
study was set up to study the influence of these lifestyle
factors on the development of CLO. Cases were CLO
patients and controls were reflux oesophagitis (RO)
patients (principally Savary – Miller grade I). In each
group there were 50 males and 48 females, and the two
groups were matched for gender, age (±3 yr) and year of
diagnosis (±3 yr). The data recorded were weight, alcohol
intake and tobacco consumption. Alcohol and tobacco
were scored as before. There were no significant differ-
ences in any of the lifestyle factors studied between CLO
and RO patients.
Length of Barrett's oesophagus segment: demographic associations 
and cancer risk
Some reports have suggested a higher incidence of AC in
longer CLO segments, yet AC has also been described in
short CLO segments (≤3 cm) [55]. We therefore reviewed
1000 medical records of CLO patients on our database.
Data on age, gender, BMI, tobacco and alcohol use, seg-
ment length at CLO diagnosis and presence of AC were
extracted. Histology and segment length were available
from 625 records. The distribution of AC according to seg-
ment length is shown in Table 7. The risk of overall or
incident cancers was greater for short segment CLO (≤3
cm) than for longer segment CLO (3 – 6 cm) but the great-
est risk is for segments >6 cms (Pearson A2 p = 0.04). There
was a small non-significant increase in CLO length with
age but no correlation between gender, BMI, or tobacco
and alcohol consumption and segment length.
Conclusions from UKBOR studies
There are a number of conclusions that can be drawn from
the analyses of the UKCLOR database, namely: -
1. That the Male to female ratio of CLO patients (1.7) is
approximately double that of AC patients (3.0)
2. Mean age at diagnosis in male CLO patients is lower
(62.0 years) than in female CLO patients (67.5 years). The
same applies to AC, mean ages at diagnosis being 64.7
years in males and 74.0 years in females.
3. Peak age at diagnosis of CLO is 60–69 years in males
and 70–79 years in females.
4. Overall prevalence of AC in CLO is 3.5%, being 4.0%
in males and 2.5% in females.
5. There appears to be very little geographical variation in
CLO patient characteristics throughout the UK. The excep-
tion is Scotland, where both the mean and the peak age at
diagnosis are lower.
6. Previous alcohol and tobacco use do not appear to
affect the risk of developing CLO; obesity may be a risk
factor in younger CLO patients.
7. Risk of AC is greatest for >6 cm segments of CLO but is
greater for short (≤3 cm) segment Barrett's than for seg-
ments >3 ≤ 6 cm.
The malignant risk
The overriding importance of Barrett's CLO is the risk of
development of oesophageal adenocarcinoma (AC).
Between 5–10% of patients with CLO will develop aden-
ocarcinoma, the annual risk in surveillance programmes
being 0.5–1%, which is 30–125 times that of the general
population [56]. Of particular concern is the escalating
incidence of AC, which has increased eightfold in Western
Europe in the last three decade, a rate of increase greater
than that of any solid tumour. Three decades ago AC com-
prised less than 10% of oesophageal tumours, a dramatic
increase in this proportion first described in the 1980's,
has occurred such that AC now represents over 50% of
oesophageal tumours in most UK units [57]. Not every-
one with CLO has a similar risk of developing AC and
much work has been done to identify risk factors that
increase the risk. The risk factors which have been identi-
fied are broadly divisible into demographic, pathophysio-
logical, environmental, histopathological and molecular
genetic.
Table 7: Distribution of AC according to CLO segment length
CLO segment length Overall ≤3 cm >3 ≤ 6 cm >6 cm
No of CLO 625 170 253 202
No of AC 28 10 4 14
All AC (% CLO) 4.5 5.8 1.6 7.1
Incident AC (% CLO) 1.5 1.8 0.8 2.1Page 6 of 21
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AC occurs almost exclusively in white males. In the USA,
AC occurs in 2.5 per 100,000 males and 0.3 per 100,000
females, giving a M: F ratio of 8:1 [56]. In the UK, where
there are several epidemiological differences from the
USA, the M: F ratio is 3–4:1 [33]. Obesity is a risk factor in
several series, the risk being proportional to the degree of
obesity, with an odds ratio (OR) of 3.0 in the fourth quar-
tile of the BMI range [58,59]. There is an increasing inci-
dence of genetic factors in the genesis of both CLO and
AC, familial cases of both having been documented, and
reflux is more prevalent among siblings than spouse con-
trols for both CLO and AC [60].
Pathophysiological
Whilst is it accepted that gastro-oesophageal reflux disease
(GORD) is a precursor lesion of CLO and CLO is a pre-
malignant lesion. A Swedish population-based study
showed chronic, long-standing GORD to be a risk factor
for AC independent of CLO, with an overall OR of 7.7 for
chronic GORD and 43.5 for severe GORD of more than
20 years duration [61]. Despite the fact that over 90% of
CLO patients have a hiatal hernia (HH), the presence of
an HH was found to be a risk factor for AC in two case-
controlled studies with multi-variate analysis, the risk
being proportional to the HH length [62,63]. In terms of
reflux parameters, those with AC had higher levels of acid
exposure (mean % TT pH < 4, 20 v 16) and lower resting
lower oesophageal sphincter pressure (LOSP) (mean
LOSP 6 v 10 mmHg) than those with uncomplicated CLO
[63]. The combination of duodeno-gastric reflux (DGR)
and GORD appears to be a strong risk factor, culminating
in oesophageal exposure to alkaline duodenal contents.
An increased risk of AC following partial gastrectomy has
been documented for some time [39] and measurement
of duodenal content reflux by Bilitec monitoring has
shown a progressive increase in those refluxers developing
CLO, and those CLO patients developing AC [64].
Environmental
Dietary factors have been studied extensively, with con-
flicting evidence of low fruit intake as a risk factor [58]
although one study has demonstrated increased AC risk in
females with dietary deficiencies of vitamins A, C, E and
folate [65]. More recent studies have postulated that die-
tary nitrate present in fertilisers may be a risk factor [66].
Smoking and alcohol ingestion have been studied exten-
sively as putative risk factors with conflicting results. Few
series have reported smoking as a risk factor with an OR
of around 2.5, but proportional to the extent and duration
of exposure [65,67], although some failed to find
increased risk [32,35]. In most series alcohol was not a
risk factor [61,63,67] whilst in one series which studies
wine consumption, it had a protective effect [68].
Drugs, which relax the LOS, such as nitro-glycerine, ami-
nophylline, anticholinergics and calcium channel block-
ers, have been found to increase risk with an OR of 3.8 in
several studies [59,69]. The effect of acid-suppressing
drugs is controversial, with an OR of 3–4 in two series
[61,70], but two series showing no increased risk [69,71].
Several series have reported infection with H. pylori as a
negative risk factor, particularly the CagA strain [70,72].
Histopathological
Many series document increasing risk of AC with increas-
ing length of Barrett's segment, particularly so when the
segment length exceeds 6 cm [62,63,67]. As a conse-
quence, it is generally assumed that the AC risk in short
segment CLO (SSBO) is relatively low. However, in a
study conducted by the UKBOR which looked at AC risk
in 625 patients, 27% of whom had SSBO, the greatest risk
in segments >6 cm was confirmed, but, somewhat surpris-
ingly, the risk in SSBO was three times higher than that in
CLO segments between 3–6 cm in length [55].
The most important risk factor of all in CLO is the pres-
ence of dysplasia, and particularly high-grade dysplasia
(HGD) in the presence of which between 16–59%
develop AC [73,74]. Within HGD, the presence of a raised
lesion, ulceration and multifocality of HGD all increase
the risk of AC. Multifocality of HGD is associated with an
OR of 5.4 of AC, the corresponding figure for a raised
lesion being 3.8. If HGD is complicated by ulceration,
80% develop AC [72-76]. In of low-grade dysplasia (LGD)
overall risk is less than that with HGD at 5–28% [72,73].
However, the diagnosis of LGD is very subjective with sig-
nificant inter-observer variation, but it has been shown
that where two pathologists agree a diagnosis of LGD, the
incidence of AC is 41% and when three agree, its 80%
[75].
The challenge for the future is to develop identifiers of
high-risk comparable to dysplasia and its complications,
but at a much earlier stage in the process of genomic insta-
bility and the principal hope lies in the identification of
appropriate molecular markers.
The molecular biology of Barrett's oesophagus
Two main steps are implicated in the process of oesopha-
geal adenocarcinoma development. The oesophageal
squamous epithelium first undergoes a metaplastic
change into a columnar type epithelium, termed Barrett's
oesophagus. This metaplastic change may then be fol-
lowed by progression to AC through a series of his-
topathological changes termed dysplasia according to the
multi-step model of carcinogenesis [77]. Even though
patients with CLO have a 125-fold increase risk of devel-
oping AC compared to patients without CLO [78,79], thePage 7 of 21
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still remains unclear whether it is predominantly environ-
mental or genetic factors that determine the progression
to adenocarcinoma.
Development of Barrett's oesophagus
There is plenty of patient data to suggest that gastro-
oesophageal reflux has an important role to play in the
development of metaplasia in the distal oesophagus
[80,20]. Three theories have emerged: (1) transdifferenti-
ation of stem cells from the basal squamous cells, migra-
tion of (2) submucosal gland cells or (3) gastric cells to
colonise the damaged squamous mucosa. Nevertheless,
very little evidence is available to test these hypotheses or
to determine the signalling pathways implicated in the
metaplastic process. The lack of reliable animal or in vitro
models does not facilitate the research.
The morphological characterisation of CLO when com-
pared to other glandular epithelia such as gastric and duo-
denal mucosa is complex. Barrett's oesophagus is a mosaic
of three main types of columnar epithelium: a junctional
zone of gastric cardia type epithelium, a gastric fundic
type and a columnar epithelium with intestinal features
characterised by goblet cells (sometimes termed special-
ised intestinal metaplasia) [6]. In 1996 Spechler suggested
that there should be an alternative classification for the
metaplasia depending on the presence or absence of spe-
cialised intestinal metaplasia since it is the intestinal
metaplasia type which confers the highest risk for malig-
nancy [81,11]. Intestinal metaplasia is classified in several
ways depending on how strongly it resembles the small
intestinal epithelium [82,83]. Metaplasia which is very
similar to the small intestine is referred to as complete,
whereas that which differs from it is termed incomplete.
The complete type (or type 1) should contain absorptive
cells that do not secrete mucus, have a well-defined brush
border containing enzymes such as disaccharides. There
may also be occasional paneth cells. In contrast, incom-
plete intestinal metaplasia (types 11 and 111/11B, which
is more common) is composed mainly of 'intermediate'
columnar cells that secrete mucus. It also contains goblet
cells that secrete sulphomucins, sialomucins or both. The
clinical relevance of these histopathological subtypes in
terms of predicting cancer risk is not clear and does not
currently contribute to the diagnosis or patient manage-
ment. CLO is also regarded to be a hyperproliferative epi-
thelium, although a review of the literature is somewhat
conflicting [84-88]. The proliferative status may be impor-
tant in determining the likelihood of cancer progression.
Molecular factors implicated in dysplasia development 
(Table 8)
Growth factors
Epidermal growth factor (EGF), its receptor (EGFR) and
transforming growth factor alpha (TGFα) have mitogenic
activities and have been widely implicated in cancer
development. Increased expression of EGFR and TGFα
has been demonstrated as CLO progresses to AC [89-91],
and patients over expressing TGFα and EGFR [92] have
been shown to have lymph nodes metastasis and a poor
prognosis [93]. EGF was found to be over expressed in
intestinal metaplasia compared with cardiac, fundic meta-
plasia and normal gastric mucosa [94,95] with maximal
expression in oesophageal AC [94-96]. c-erb-B2 (Her-2/
Neu), a truncated version of EGFR, involved in cell prolif-
eration and differentiation [97] is expressed in late stages
of carcinogenesis [98-102] in a subset of the cancer
patients [103] and is associated with a poor prognosis
[98]. Transforming growth factor beta (TGFβ) is a potent
anti-proliferative agent acting through two receptors
(TGFβRI and TGFβRII) and its signalling molecules called
Smad 2, 3 and 4. The loss of function of TGFβ signalling
in Barrett's associated adenocarcinoma could be related to
Smad 4 mutations [104,105] or to the loss of mRNA
expression of TGFβRII [106,107].
The increase of growth factors and their associated recep-
tors suggests the possibility of an autocrine stimulation of
growth, unimpaired by negative regulators.
Oncogenes
The products of the ras family (H, K and N) of oncogenes
are believed to modulate cell growth by abrogation of cell
growth requirements [108]. Investigators were unable to
identify c-ras mutations in dysplastic and non-dysplastic
CLO mucosal biopsy or in cancer samples [95,109]. Muta-
tions of codon 12 of the k-ras gene were found to be rare
in CLO but increased in frequency along the progression
to AC [110,111]. Amplification of k- and h-ras were only
seen in established AC, suggesting that this is a late event
in carcinogenesis [112].
The oncogenes c-myc, c-fos and c-jun encode for nuclear
proteins involved in transcriptional regulation. Transient
growth factor stimulation of those oncogenes can lead to
a sustained increase in cell proliferation [113]. Amplifica-
tion of c-myc was only seen in dysplastic CLO and the per-
centage of cases with amplification increased with
progression to AC [114,115], nevertheless an increase in
c-myc protein expression was seen in CLO and increased
with progression to AC [116]. As CLO becomes malig-
nant, there is a shift of localisation of c-myc and c-jun
from the nucleus to a more diffuse cytoplasmic localisa-
tion [95,116].Page 8 of 21
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abnormal epithelial cell proliferation independent of the
usual growth requirements.
Cyclo-oxygenase-2 and inducible nitric oxide
Expression of Cyclooxygenase-2 (cox-2) and inducible
nitric oxide (iNOS) and mediators of were shown to be
high in CLO and low grade dysplasia when compared to
normal squamous oesophagus, gastric mucosa and aden-
ocarcinoma [117-121]. Cox-2 expression was shown to be
higher in the distal end of the oesophagus, where AC
tends to occur, when compared to the proximal end
[122]. Furthermore, Cox-2 stimulation was shown to
induce proliferation in an in vivo system [124]. This sug-
gests an early involvement in the carcinogenesis process
by stimulation of mucosal proliferation.
Luminal factors
Gastro-oesophageal refluxate, the major factor associated
with the development of CLO contains bile salts and
Table 8: Summary of the molecular alterations studied in the progression of Barrett's associated carcinogenesis (list none exhaustive).
Increased proliferation
Growth factors Receptors/effectors
TGFα
EGF EGFR
C-erb-B2 (Her-2/Neu)
TGFβ TGFβR 2
Smad 4
p27
Mediators of inflammation
Cox-2 PKC
INOS
TNFα β catenin, c-myc
Luminal components
Gastrin CCK2
Bile salts Cox-2
Acid Cox-2
PKC
p38MAPK
JUNK
p44ERK
Oncogenes
Ras
Fos
Jun
c-myc
Cell cycle proteins
Cyclin D1, E, B1
Rb
p16
Avoidance of apoptosis
p53 p21(cip1/waf1)
Bcl-2
Bax
Increased invasive potential
Angiogenesis
FGF 1&2
VEGF
Cell-cell – adhesion
E-cadherin
α, β, γ catenin
APCPage 9 of 21
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cell lines, demonstrated that proliferation could be
induced through involvement of the sodium-hydrogen
exchanger (Na+-H+), a major acid-extruder in CLO cells, as
well as via activation of the p38MAPK, p44ERK1 and Jun-N-
terminal kinase (JNK) enzymes [124,125]. Pulsatile acid
exposure of cell lines was shown to suppress apoptosis via
the p53 pathway and to stimulate proliferation possibly
through the MAP kinase pathway [126]. Cox-2 expression
was also induced by acid and bile salts in ex vivo experi-
ments [127,128] in a protein kinase C (PKC) dependant
manner. As well as this in vitro work, ex vivo studies have
also suggested a hyerproliferative effect of acid and bile
exposure on the Barrett's epithelium [129,130]. This has
implications for the use of reflux-suppressive therapies in
patients with CLO. However, it should be remembered
that the induction of the mitogen gastrin in response to
proton pump inhibitor therapy might induce prolifera-
tion of the CLO mucosa via the cholecystokinin (CCK2)
receptor [131].
Abnormalities in cell cycle and apoptosis
Passage of cells through the restriction point controlling
the G1/S phase transition is a key element of proliferation
(Figure 1). This checkpoint, also called the restriction
point, is tightly controlled by a plethora of inhibitors of
cell cycle progression and molecules inducing apoptosis
such as p53. Aberrant expression of regulatory proteins
may lead to uncontrolled progression through the cell
cycle, instead of the normal cell cycle arrest, which is nec-
essary for processes such as DNA repair.
Hyperproliferation has been associated with progression
from CLO to AC [84-86,132]. For a tissue to become
hyperproliferative, the individual cells have to progress in
uncontrolled fashion through the restriction point.
Amplification and overexpression of cyclin D1 [133-135],
decreased expression and loss of heterozygosity (LOH) of
Rb [136-138] and increased expression cyclin E [139] as
well as accumulation of mutant p53 [140-149] as CLO
progresses to AC suggest that the G1/S transition control
system is overridden. Furthermore, inactivating hyper-
phosphorylation [150-153] or deletion of p16 [154], a
cyclin cyclin D1/CDK complex inhibitor, seems to be a
common feature of CLO carcinogenesis. p27 is inactivated
in AC and tumours lacking p27 have a more aggressive
behaviour [155].
Flow cytometry studies showed that G2/M phase accumu-
lation is found early in the progression [156]. Results
implicating cyclin B1 (expressed in G2 phase of the cell
cycle to regulate entry into mitosis) overexpression in the
progression to cancer, confirmed this first study [157].
Further to an increase in p53 expression, apoptosis may
be avoided in the progression from CLO to AC via abnor-
mal Bcl-2 and Bax expression [119,158-162]. The expres-
sion profile of p21(cip1/waf1) is subject to controversy
[158,159,163,164] but p21(cip1/waf1) does not seem to
inhibit proliferation in the context of CLO carcinogenesis.
Factors leading to an increased invasive potential
Angiogenesis, characterised by the stimulation of migra-
tion and proliferation of capillary endothelial cells creat-
ing new vasculature, is an important mechanism by which
metastases occur. Acid and basic fibroblast growth factors
(respectively FGF1 and FGF2) and vascular endothelium
growth factor (VEGF) are key players in this process [165].
FGF 1 and 2 expression was shown be increased as CLO
progresses to AC [166-168]. In AC, VEGF expression cor-
related with the level of the vasculature, which in turn cor-
related with the presence of lymph nodes and distant
metastasis. It has been mentioned that the salmon-pink
colour of the CLO mucosa could be due to the increased
presence of blood vessels when compared to normal
squamous epithelium [170,171].
The calcium-dependant cadherin-catenin membrane
bound complex is a key factor for maintaining epithelial
integrity, cell polarisation and cell-cell adhesion. Loss of
cell-cell interaction resulting from down-regulation of E-
cadherin may trigger and facilitate metastasis [171]. Many
reports have commented on the increasingly low levels of
E-cadherin (protein and mRNA level) and α- and β-cat-
enin in the progression from normal squamous epithe-
lium to adenocarcinoma [172-176]. This trend of down-
regulation was shown to correlate with poorer survival,
invasion, and metastasis [172] as well as with the stage
and grade of the cancer [173]. Interestingly, a subset of
patients was shown to have nuclear localisation of the E-
cadherin-β-catenin complex [173,174,177,178]. A recent
study demonstrated that tumour necrosis factor alpha
(TNFα) induces c-myc expression via β-catenin [116]. The
role of the nuclear E-cadherin-β-catenin complex in this
system is not clear and further investigation is warranted.
The adenomatous polyposis coli gene (APC) product is a
binding partner for the catenin and links trans-membrane
cadherins to the actin filaments of the cellular cytoskele-
ton. APC gene alterations are highly specific to gastroin-
testinal carcinogenesis. Alterations in the APC gene were
detected in dysplastic CLO and associated AC but not in
non-dysplastic CLO and normal mucosa [154,179,180].
Hypermethylation of the APC locus was found in the
majority of AC [181]. Hence, molecular changes in the
dysplasia carcinoma sequence set the stage for invasion
and metastases to occur.Page 10 of 21
(page number not for citation purposes)
World Journal of Surgical Oncology 2004, 2 http://www.wjso.com/content/2/1/12Overview of the G1/S transition of the cell cycleFigure 1
Overview of the G1/S transition of the cell cycle. Following stimulation of proliferation, accumulation of cyclin D1-CDK4/6 
complex will lead to phosphorylation of retinoblastoma protein (pRB) thus allowing E2F to promote expression of genes lead-
ing to progression from the G1 phase to the S phase of the cell cycle. Cyclin E-CDK2 allow further phosphorylation of RB cre-
ating a positive feedback loop. Intracellular or extracellular factors such as DNA damage or lack of required growth factors can 
influence this process in a negative fashion (e.g.: through p21 or p53).Page 11 of 21
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Barrett's carcinogenesis are gradually being documented
although the sequence by which these abnormalities
occur seems to be non-linear and complex [182]. Most of
the studies that have been carried out to date are descrip-
tive. Unfortunately, it has proved hard to develop models
for dynamic studies although progress is being made
[130,183]. Work is still needed in order to understand the
driving forces behind Barrett's carcinogenesis so that
progress can be made in identifying clinically useful diag-
nostic markers and novel therapeutic strategies.
Management of uncomplicated Barrett's
The management of uncomplicated Barrett's comprises
treatment designed to influence the natural history of the
condition and surveillance to detect dysplastic change,
which will be considered later.
The pathophysiological features of Barrett's oesophagus as
outlined above have implications regarding management
and its efficacy. Barrett's oesophagus clearly represents the
extreme end of the pathophysiological spectrum of gastro-
oesophageal reflux disease and this is compounded by the
fact that many patients have few or no symptoms due to
the relative insensitivity of columnar mucosa to acid per-
fusion compared with patients with erosive oesophagitis
[24]. Despite these factors, many authorities advocate no
treatment for Barrett's oesophagus unless symptoms are
present. Those who believe that the objectives of manage-
ment of CLO are more to do with an attempt to influence
the natural history of the condition than symptomatic
relief advocate such modalities as pharmacological acid
suppression, endoscopic ablation or anti-reflux surgery.
At the present time, the optimal management of CLO is
unknown and these modalities are applied largely on the
basis of personal preference, although a large multi-centre
randomised study to address this issue is proposed.
Pharmacological acid suppression
This clearly has theoretical advantages, being the least
invasive form of long-term therapy, particularly as Bar-
rett's oesophagus is predominantly a disease of the eld-
erly, the mean age being around 63 [33]. Although the
development of squamous islands following PPI therapy
is well recognised, circumferential regression of the
columnarised segment is rare, a meta-analysis of six sub-
sequent series showing no evidence of regression [184].
Several studies report the difficulty of normalising
oesophageal acid exposure in Barrett's patients, even using
doses equivalent to Omeprazole 80 mg daily and even
when amelioration of symptoms, if present, has occurred
[185-187]. This is likely to relate to the pathophysiology
of this group of patients previously alluded to and the
consequences of incomplete acid suppression is a matter
of concern in this group of patients, since it has been
shown that Barrett's oesophagus cells in culture exhibit a
greater degree of proliferation and de-differentiation
when exposed to intermittent pulse acid exposure com-
pared to no acid exposure and even continuous acid expo-
sure [130]. It is, therefore, possible that inadequate levels
of acid suppression may have contributed to the rising
incidence of adenocarcinoma of the oesophagus and gas-
tric cardia [188,189]. It has been recommended to try to
overcome this problem that an H2 receptor antagonist
should be added at night, possibly combined with a prok-
inetic agent and that the dose of PPI should be titrated
against the level of oesophageal acid exposure on 24 hr
pH monitoring in order to optimise the effect of acid sup-
pression therapy [185]. There remains, however, the prob-
lem of abnormal duodenal juice exposure, which
although reduced as measured by Bilitec monitoring, on
PPI therapy, presumably due to a volume-reduction effect,
such exposure is normalised in less than 50% of patients
[190].
Endoscopic ablation
While endoscopy is considered to offer a relatively poor
return in assessing uncomplicated symptomatic GORD
and lack of impact in altering medical treatment [191], it
offers a useful therapeutic option for mucosal ablation of
metaplastic epithelium and putative regeneration of squa-
mous lining [192]. It could be argued that ablative tech-
niques should be reserved for areas of dysplastic change
only and certainly further studies are needed to define the
indications, efficacy and relative safety of the various
modalities of treatment.
Ablative modalities can be divided into thermal and non-
thermal. Thermal methods involve coagulation and
vaporisation of epithelium using an Nd-YAG or GaAIAs
semi-conductor diode laser. A more recent and less expen-
sive option involves the use of the Argon plasma coagula-
tor (APC) [194]. While the learning curve is shorter for the
use of APC, care must be taken to limit the depth of ther-
mal injury to prevent undue stricture formation and per-
foration by penetrating through the deeper layers with all
forms of thermal therapy. Photodynamic therapy (PDT)
produces a cytotoxic action via the release of singlet oxy-
gen when light of a specific wavelength is directed onto
the tissue sensitised by the uptake of a photosensitising
drug. The pro-drug, 5 aminolaevulinic acid, which con-
verts to protoporphyin IV, the last step in the haem bio-
synthetic pathway, is selectively taken up by the mucosa
and has yielded promising results as an agent for PDT in
the treatment of Barrett's metaplasia and dysplasia [195].
Since ALA is confined to the mucosa, stricture formation
does not occur but this complication has been found in
excess of 30% of cases treated by PDT where mTHPC or
Photofrin have been used as photosensitisers [196].
Development in the light delivery systems and new gener-Page 12 of 21
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of PDT. Endoscopic ablation techniques, performed in a
reflux-free environment using either high dose PPI ther-
apy or fundoplication result in squamous re-epithelialisa-
tion in 50–80% of patients, although residual islands of
columnar metaplasia remain in 20–60% depending on
the depth of injury [192-196].
There remains doubt as to the status of islands of colum-
nar metaplasia covered by squamous regeneration follow-
ing the use of ablative techniques and it is recommended
that endoscopic ablation techniques should only be per-
formed in the context of prospective randomised trials.
Anti-reflux surgery
Fundoplication has the theoretical advantage of being
able to correct lower oesophageal sphincter failure and
the frequently associated hiatal hernia and producing
complete and continuous control of abnormal acid and
duodenal juice exposure in 80–90% of patients. Two stud-
ies have demonstrated a greater degree of symptom con-
trol and healing of associated strictures and a lower
incidence of new strictures after fundoplication compared
to acid suppression therapy [198,199]. There are consider-
ably more reports of regression following anti-reflux sur-
gery, although regression is rarely complete and occurs in
only 10–44% of patients [198-203]. However, it is per-
haps of greater importance what is happening at cellular
level rather than whether or not macroscopic regression
occurs.
The effect of successful anti-reflux surgery on the inci-
dence of AC is unknown and indeed adenocarcinoma has
been reported after successful anti-reflux surgery [201]. It
is theoretically possible that anti-reflux surgery may be
effective in preventing adenocarcinoma if performed suf-
ficiently early in the sequence of genomic instability, but
that a point may be reached beyond which no form of
treatment can prevent the development of AC. This con-
cept is supported by the findings of a study from the Mayo
Clinic in which 113 patients with CLO were followed up
for up to 18 years after anti-reflux surgery. Although 3
patients developed AC, these were all in the first 3.3 years,
after which no carcinomas developed [204]. The inci-
dence of AC in this series was 1:274 patient years of follow
up, considerably less than the mean of 1:80 patient years
of follow up reported from surveillance series of patients
on acid suppression therapy [205].
Notwithstanding the apparent theoretical advantages of
fundoplication over acid-suppression therapy, which
need to be confirmed by randomised control trials, it
should be remembered that CLO is a condition largely of
old age and only approximately 50% of patients will be
below the age of 70 and fit for consideration of surgery.
However, it should certainly be considered in younger
patients and particularly those with risk factors for devel-
opment of AC, such as those with a long history, early age
at diagnosis, Barrett's segment greater than 7 cm and doc-
umented pathological alkaline exposure.
Surveillance
Background to screening and surveillance
Both screening and surveillance have been advocated for
CLO in an attempt to reduce the mortality from AC.
Screening refers to a programme to identify individuals
with CLO who have not previously been diagnosed. Sur-
veillance refers to the follow-up of patients with known
Barrett's oesophagus. Surveillance programmes only
review a small proportion of the population at risk since
only a minority of patients with Barrett's oesophagus are
clinically diagnosed [25].
At the current time there are no randomised controlled tri-
als examining the clinical benefit or cost-effectiveness of
endoscopic screening for Barrett's oesophagus in either
the general population or in patients with reflux disease.
In the future non-endoscopic screening programmes tar-
geted at individuals at highest risk for developing AC may
be possible. For this to become a reality we will need to
depend on molecular epidemiological studies to identify
predictive markers with high sensitivity and specificity
and technological developments to implement this, in an
ethically acceptable and cost-effective manner. Since the
majority of the data at the current time pertains to
surveillance.
Rationale for surveillance
Most patients with AC present with dysphagia, and
despite advances in multimodal treatment the five-year
survival rates of symptomatic oesophageal carcinomas
remain less than 10% [206,207]. Since the major determi-
nant of outcome is the stage of the cancer at presentation
[208], early detection of AC is essential in order to signif-
icantly improve survival rates. The identification of a
multistage process of cancer development, akin to that
described in colon carcinogenesis, provides the rationale
for endoscopic surveillance in patients with diagnosed
CLO [77,78,209-211]. Several studies have shown a sig-
nificant improvement in the 5-year survival of patients
with surveillance-detected adenocarcinoma [212-214],
although these studies are generally limited by their small
sample size.
There have been no large studies, which have compared
the life expectancy of patients with Barrett's with the gen-
eral population. The only report in the literature suggests
that the actuarial survival of patients with Barrett's
oesophagus is no different from general population [215].
The flagging study in progress by the UK Barrett'sPage 13 of 21
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Risk of progression
The value of surveillance hinges on the actual risk of can-
cer in patients with CLO [216]. A meta-analysis of 25
studies conducted between 1984 and 1998 demonstrated
that the number of incident cancers ranged from 1 in 35
to 1 in 441 patient years of follow-up, with a mean cancer
incidence in these studies of 1 in 138 patient years [217].
The wide variation in cancer incidence may be as a result
of the retrospective nature of the studies, diagnostic varia-
tion, surveillance protocol variation (number of biop-
sies), variation in outcome data (death, dysplasia or
cancer), and publication bias (negative studies tend not to
be published).
At the current time the histopathological assessment of
dysplasia is used to predict the likelihood of cancer devel-
opment. In a recently reported retrospective cohort study
of 79 patients with high-grade dysplasia 4.5 (5%) had
cancer at 1 year and 12 (16%) had cancer on follow-up
(mean 7.3 years) [73]. However, concern has been
expressed about the over-diagnosis of dysplasia in this
cohort. Another group demonstrated that the likelihood
of cancer was dependent on the extent of high-grade dys-
plasia (focal or diffuse) [74], although this has not been
confirmed in a subsequent study [218]. These studies are
hampered by the subjectivity of the diagnosis of dysplasia
and hence more specific markers of malignant potential
are badly needed [219], (see section on molecular patho-
genesis). When deciding on the merits of surveillance pro-
grammes it should be borne in mind that 40% of patients
with high-grade dysplasia have been found to harbour
foci of carcinoma in their resection specimen [220]. The
practical problems associated with surveillance are sum-
marised in Table 9.
From an economic point of if the incidence is 1% 2–3
yearly surveillance endoscopy would be cost-effective;
whereas if the incidence is 0.5% 4–5 yearly would be rec-
ommended [221,222]. As a result of the apparent geo-
graphical variations in cancer incidence (e.g. UK versus
USA) different surveillance intervals may be
recommended.
Local UK experience
There is a wide variation in the surveillance protocols
undertaken in the UK. Surveillance was conducted in
Leicester from 1984 to 1999, 143 out of 409 patients were
eligible for surveillance using their diagnostic criteria with
a 70 year age cut-off and in 1999 only 8 were still in the
programme. Quadrantic biopsies were taken from the
midpoint of the Barrett's segment rather than every 2 cm
along the Barrett's length according to the Seattle protocol
[223]. Over the 15 years 5/143 developed carcinoma – 2
had a stricture at the time enrolment, 2 were programme
defaulters and hence the programme itself only identified
one subject [44]. This study is probably more informative
about the practical difficulties in administering such a
programme, rather then being informative about the
value of surveillance itself. Implementation of a rigorous
surveillance protocol In an East London hospital (Old-
church, UK) in line with the Seattle guidelines, for
patients with specialised intestinal metaplasia who were
fit enough for surveillance (no age cut off) significantly
increased the yield of high-grade dysplasia and cancer
detection [224].
The World Health Organisation has criteria for screening/
surveillance and it is not clear to what extent Barrett's
oesophagus currently meets these criteria. In order to
address these questions a prospective randomised con-
trolled trial of surveillance versus no surveillance is
required. Such a study would require 10 yr study with
5,000 patients and the ethical considerations of a no-sur-
veillance arm would have to be carefully considered
[222]. At the current time the American College of Gastro-
enterology have made clear recommendations for screen-
ing and surveillance based on the best available evidence
[225]. The British Society of Gastroenterology is currently
in the process of drawing up their guidelines (Prof. Tony
Watson is Chairman of the Working Group). It is certainly
clear that we need an international consensus on our def-
inition(s) of Barrett's oesophagus and dysplasia so that
the outcomes of surveillance protocols can be usefully
compared.
Table 9: Common problems encountered with Barrett's surveillance
• Dysplastic lesions are often flat and indistinguishable endoscopically
• Variations in diagnostic criteria for Barrett's oesophagus and dysplasia
• Wide variations in local protocols (e.g. how often surveillance should be conducted if at all, the number of biopsies)
• Imaging protocols do not achieve subcellular resolution and biopsies are still required
• Submucosal deep abnormalities may not be detected even when the area is biopsied
• Sampling bias (dysplasia may be focal, patchy or diffuse)
• Surveillance is time consuming and costlyPage 14 of 21
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It is likely that this discussion will become a thing of the
past. Currently our methodology is grossly inadequate.
Ongoing research into the diagnosis and therapy will rad-
ically alter our approach to this subject. For example,
considerable progress is already being made into methods
for predicting which patients are at high risk. The method-
ologies currently being evaluated include serum markers,
genetic susceptibility profiles and molecular markers
using non-endoscopic brushings. In addition, endoscopic
methods are being evaluated to target biopsies using tech-
nologies such as vital dyes (e.g. methylene blue spraying)
in conjunction with zoom endoscopy and optical biopsies
or virtual biopsy techniques such as elastic scattering spec-
troscopy and fluorescence (autofluorescence or drug
induced fluorescence) [226], (Table 10).
At the current time the gold standard treatment is an
oesophagectomy, which has an associated morbidity and
mortality of between 5 and 10%. However, with the devel-
opment of endoscopic treatments this will obviate the
need for surgery especially in elderly patients with comor-
bidity. These treatments include ablation therapies such
as photodynamic therapy and endoscopic mucosal resec-
tion of visible lesions [227-229]. Chemoprevention strat-
egies such as profound acid suppression [230] and COX2
inhibitors [231] are also being discussed. If these or alter-
native therapeutic agents could significantly reduce the
cancer risk in the population at risk then surveillance may
become a thing of the past.
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